Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Ранг среди акций #27
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Цена акции
$265.95
Рыночная капитализация
$469.88B
Изменение (1 день)
0.34%
Изменение (1 год)
19.48%
Страна
US
Торговля AbbVie Inc. (ABBV)

Категория

Коэффициент P/E для AbbVie Inc. (ABBV)
Коэффициент P/E на September 2026 TTM: 73.73
Согласно последним финансовым отчетам и цене акций AbbVie Inc., текущий P/E (TTM) составляет 73.73. В конце 2024 у компании был P/E на уровне 73.48.
История P/E компании AbbVie Inc. с 2009 по 2026
P/E на конец каждого года
Год P/E коэффициент Изменить
2026 (TTM) 73.73 -23.85%
2025 96.82 31.76%
2024 73.48 30.42%
2023 56.34 132.99%
2022 24.18 16.46%
2021 20.76 -46.34%
2020 38.70 132.60%
2019 16.64 -33.40%
2018 24.98 -14.08%
2017 29.07 70.40%
2016 17.06 -8.83%
2015 18.71 -68.19%
2014 58.84 189.43%
2013 20.33 99.06%
2012 10.21 -38.01%
2011 16.47 21.70%
2010 13.54 10.97%
2009 12.20 0.00%
P/E для схожих компаний или конкурентов
Компания P/E Ratio Разница P/E Страна
38.12 -48.30%
US
30.79 -58.24%
US
22.25 -69.82%
CH
114.95 55.91%
US
22.23 -69.84%
CH
Как читать P/E Ratio?

Коэффициент цена/прибыль (P/E Ratio) отражает соотношение между ценой акции компании и её прибылью на акцию.
Низкий, но положительный P/E говорит о том, что компания приносит высокую прибыль при низкой оценке и может быть недооценена. Высокий отрицательный (близкий к 0) P/E указывает на значительные убытки.

Компании с P/E выше 30 или отрицательным считаются "акциями роста" — инвесторы ожидают роста или будущей прибыли.

Компании с положительным P/E ниже 10 считаются "ценностными акциями", т.е. уже прибыльны, но с низким потенциалом роста.